From radiology and cardiology to digital pathology and multi-specialty imaging, Hyland enables a single, secure, and interoperable imaging record that enhances clinical decision-making CLEVELAND , Nov. 20, 2025 /PRNewswire/ — Hyland, the pioneer of the Content Innovation Cloud™, will be…
Author: Ken Dropiewski
Catheter Precision Announces Successful LockeT Launch in South Africa
FORT MILL, S.C., Nov. 20, 2025 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (VTAK – NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announces the rapid commercial uptake of its LockeT closure device in South Africa.
Investor Insights: Kate Sonders of Sonder Capital Discusses Disease States and Robotics
Okami Medical Announces $45 Million Financing and New CEO Appointment to Drive Next Phase of Growth
ALISO VIEJO, Calif., Nov. 19, 2025 /PRNewswire/ — Okami Medical, a medical technology company pioneering novel vascular embolization solutions, today announced the successful close of an oversubscribed $45M financing led by new investor Gilde Healthcare with participation from existing…
November Issue of Journal of Cardiac Failure-Intersections Highlights Advances in Right Ventricular Reserve, Revascularization Strategies, and LVAD Deactivation
The second issue of the open-access journal showcases multidisciplinary heart failure research and the many intersections that shape patient care. WASHINGTON, Nov. 19, 2025 /PRNewswire/ — The second issue of the Journal of Cardiac Failure-Intersections, online now, delivers a diverse…
Qure.ai partners with Microsoft to increase access to its lung cancer detection and management suite in the U.S.
Accelerating early detection, reducing clinician burden, and enhancing patient outcomes New York, November 18 2025: Qure.ai, a TIME100 most influential company and global leader in digital healthcare, today announced its collaboration with Microsoft. Qure.ai will onboard its end-to-end lung cancer detection, measurement and management suite of AI-powered solutions onto […]
Frank J Veith and Rasit Dinc Evaluate Next-Generation Technologies in Vascular Treatments
AI-driven innovations in digital health and imaging were discussed at the VEITH Symposium, where Frank Veith and Rasit Dinc evaluated the impact of next-generation technologies on vascular treatments NEW YORK, Nov. 19, 2025 /PRNewswire-PRWeb/ — During a special session at the 52nd annual…
Spryte Medical Receives FDA IDE Approval to Initiate “INSYTE” US Pivotal Trial evaluating the nOCT Imaging System during Brain Aneurysm Treatment
BEDFORD, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) — Spryte Medical, a pioneer in intravascular neuro imaging, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the INSYTE pivotal trial. The trial will evaluate the safety and effectiveness of Spryte’s neuro Optical Coherence Tomography (nOCT) imaging system for use during intracranial aneurysm treatment procedures.
Amy Rudolph, PhD, Joins Thryv Therapeutics’ Board of Directors to Support Portfolio Progression into Heart Failure
MONTREAL, Nov. 19, 2025 /PRNewswire/ – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced…
Philips and Cortechs.ai extend partnership to advance quantitative neuroimaging and strengthen Philips’ leadership in precision diagnostics in neurology
November 19, 2025Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an extended partnership with Cortechs.ai, a pioneer in quantitative neuroimaging solutions. Together, the companies will integrate Cortechs.ai’s advanced AI-enabled neuroimaging analytics directly into Philips’ MR systems [1], empowering clinicians with faster, more objective, and reproducible insights into brain health. The collaboration strengthens Philips’ leadership in precision neuro diagnostics, combining Philips’ next-generation MR technologies with Cortechs.ai’s AI-driven quantitative neuro imaging post processing software [1] to transform how neurological diseases are detected, monitored, and managed.Combining complementary expertise for smarter brain imagingUp to 25% [2] of all MR procedures are brain scans, and radiology departments face growing demand amid increasing staff shortages. At the same time, the number of patients with neurological conditions such as Alzheimer’s disease, multiple sclerosis (MS), and brain tumors continue to rise globally. Current MR interpretation of neurodegenerative diseases or neuro oncology cases depends heavily on visual assessment, introducing variability and requiring significant expertise and time in an already overloaded system.Through this extended partnership, Philips and Cortechs.ai aim to deliver more standardized and data-driven imaging. By integrating quantitative analysis tools such as brain volumetrics, lesion quantification, and tumor tracking directly into the Philips MR imaging workflow [1], clinicians gain objective, numerical data alongside images – enabling faster, more consistent, and confident diagnoses.Empowering clinicians with precision and speedThe integration of Cortechs.ai’s NeuroQuant® solutions for Alzheimer’s, MS and brain tumors within Philips’ Smart Reading environment – a cloud-based AI platform that combines imaging, reading, and reporting directly on the MR systems [1] – marks a major step toward precision neuroimaging.With this integration, clinicians can automatically receive AI-generated quantitative reports within their standard MR workflow on the MR system or PACS, without adding extra steps for technologists. The zero-click process ensures quality-checked data and standardized outputs, helping radiologists interpret brain scans more objectively, faster and with greater confidence.“By extending our partnership with Cortechs.ai, we are accelerating the transition to fully quantitative, AI-powered neuroimaging,” said Ioannis Panagiotelis, PhD, Business Leader, MRI, Philips. “This integration brings precision, reproducibility, and efficiency to neurological MR, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.”Driving productivity and improving care through AIPhilips is driving productivity and improving care through deep AI integration that tackles some of healthcare’s most pressing challenges – from workforce shortages to the growing demand for advanced diagnostics. By automatically generating quantitative reports within existing workflows, AI helps radiologists save time, improve consistency, and boost throughput. Objective numerical biomarkers enhance diagnostic accuracy, enabling more reproducible assessments and confident comparisons across time and sites. And by minimizing manual post-processing through automated, quality-controlled workflows, technologists can focus more on what matters most – delivering a better, more personalized patient experience.“Cortechs.ai’s mission has always been to empower clinicians with actionable, quantitative insights,” said Kyle Frye, Chief Executive Officer, Cortechs.ai. “By combining our advanced neuro analytics with Philips’ leading MR platform and AI infrastructure, we’re making it easier to personalize brain care and track neurological changes with precision.”Setting a new standard in precision neuro diagnosticsCortechs.ai’s NeuroQuant® solutions are already available on Philips Advanced Visualization Workspace. With this extended partnership, Philips reinforces its commitment to advancing the field of neurology – empowering healthcare providers to deliver better care for more people, in less time, with greater confidence.



